

Table S5 Baseline characteristics of participants with CKM stages 0-3 in the clinical patient cohort according to METS-IR quartiles**						
Characteristics	Overall	Quartiles of METS-IR				P value
		Q1 (<32.18)	Q2 (32.18-35.63)	Q3 (35.63-39.33)	Q4 (>39.33)	
Participants (n)	4825	1206	1206	1206	1207	
Age (years)	58.48±9.96	62.63±11.05	60.7±11.83	58.05±8.88	56.04±9.27	<0.01
Male (n, %)	2730 (56.58%)	598 (49.57%)	652 (54.09%)	718 (59.57%)	762 (63.13%)	<0.01
Married (n, %)	4139 (85.78%)	1011 (83.84%)	1026 (85.12%)	1038 (86.08%)	1064 (88.15%)	0.359
History (n, %)						
Smoking	1250 (25.91%)	322 (26.64%)	292 (24.16%)	326 (26.99%)	310 (25.68%)	<0.01
Alcohol consumption	1401 (29.04%)	334 (27.71%)	360 (29.88%)	370 (30.69%)	337 (27.92%)	<0.01
Hypertension	2261 (46.87%)	515 (42.68%)	539 (44.67%)	642 (53.21%)	565 (46.81%)	<0.01
Diabetes mellitus	600 (12.44%)	86 (7.16%)	130 (10.79%)	185 (15.32%)	199 (16.49%)	<0.01
Heart Disease	456 (9.46%)	61 (5.07%)	69 (5.73%)	103 (8.55%)	223 (18.48%)	<0.01
Medication						
Hypoglycemic drugs	4403 (29.04%)	1091 (90.49%)	1142 (94.3%)	1093 (90.72%)	1077 (88.74%)	0.223
Antihypertensive drugs	3845 (79.69%)	972 (80.59%)	1001 (83.06%)	944 (78.35%)	928 (76.86%)	<0.01
Lipid-lowering drugs	4397 (91.13%)	1092 (90.04%)	1134 (93.77%)	1106 (90.89%)	1061 (88.08%)	0.261
Clinical status *						
SBP (mmHg)	128.44±21.91	123.93±22.13	126.99±24.7	130.52±25.88	133.26±21.27	<0.01
DBP (mmHg)	76.69±12.71	72.21±10.54	75.51±11.47	79.93±12.88	81.47±13.43	<0.01
Heart rate (bpm)	70.45±11.04	70.11±12.81	70.98±10.85	70.92±10.71	70.41±12.43	<0.01
BMI (kg/m ²)	24.62±3.14	20.68±2.82	23.9±1.71	26.11±2.13	28.24±3.71	<0.01
Laboratory testing *						
FPG (mg/dL)	114.86±32.38	97.89±18.37	107.05±25.58	110.49±33.55	122.95±50.06	<0.01
TG (mg/dl)	134.8±98.68	81.27±32.98	105.12±51.55	133.3±64.52	209.8±168.86	<0.01
HDL-C (mg/dl)	52.56±14.84	62.91±15.48	55.27±11.88	49.4±10.64	41.47±9.23	<0.01
LDL-C (mg/dl)	114.11±34.71	109.06±31.93	115.29±32.48	118.33±34.83	121.54±39.65	<0.01
TC (mg/dL)	195.47±35.92	190.29±32.65	192.90±36.12	196.97±38.26	198.36±42.24	<0.01
Crea (mg/dl)	0.76±0.39	0.76±0.32	0.76±0.42	0.76±0.2	0.76±0.29	0.318
HBA1C (%)	5.22±0.93	5.05±0.54	5.14±0.94	5.27±0.81	5.44±1.35	<0.01
UA (mg/dl)	4.47±1.37	4.28±1.68	4.33±1.25	4.52±1.36	4.63±1.73	<0.01
HGB (mg/dl)	14.1±2.44	13.13±2.63	14.22±2.35	14.18±2.3	14.84±2.09	<0.01
METS-IR	35.92±9.56	27.75±2.3	33.27±1.95	37.25±1.69	42.78±8.79	<0.01
CKM syndrome stage (n, %)						<0.01
0	531 (11.66%)	249 (20.65%)	183 (15.17%)	96 (7.96%)	3 (0.25%)	
1	1110 (23.34%)	408 (33.83%)	366 (20.35%)	326 (27.03%)	10 (0.83%)	
2	2316 (48.8%)	282 (23.38%)	562 (46.6%)	615 (50.84%)	857 (71.06%)	
3	868 (17.98%)	267 (22.14%)	95 (7.88%)	169 (14.17%)	337 (27.86%)	
Stroke						
n	381	69	85	103	124	<0.01

*: Data was presented as mean ± SD
 **: Data from participants hospitalized at Shengjing Hospital of China Medical University